The Justice Department is reviewing the deals, with results unlikely to be forthcoming anytime soon. Meanwhile, both sides of the political aisle have been skeptical of how the mergers will impact the public. The difference is where they point their fingers.
While some Democrats say consolidation concerns highlight the need for health care regulation, Republicans point to them as evidence of the president’s broken promises and the adverse effects of the Affordable Care Act. Subcommittees in the House and Senate Judiciary Committees have held hearings looking into the matter.
“Lurking behind the antitrust review of these deals is the question of how much influence the Affordable Care Act had on the proposed transactions,” said House Judiciary Committee Chairman Bob Goodlatte in a statement on the hearing. “The Affordable Care Act put into place incentives for insurers to increase in size so that they can better manage costs and the heavy regulatory burden and operational constraints imposed by the law.”
Clinton has adamantly expressed her support for the ACA, saying she will build on and strengthen it. But her policy proposals tackle issues the law left alone, namely the steep rise in prescription-drug costs, or areas that don’t go far enough.
Last month, Clinton released a series of policy proposals aimed at health care costs, including: requiring insurers and employers to provide up to three sick visits to a doctor annually without having to first meet a plan’s deductible; providing a progressive, refundable tax credit of up to $5,000 per family for out-of-pocket costs; enforcing and broadening the ACA’s transparency provisions; creating a “fallback process” for states that do not have the authority to modify or block health-insurance premium-rate increases; and building on value-based delivery-system reforms.
Then, too, she mentioned mergers, saying she would enforce antitrust laws while monitoring health-industry consolidation and mergers. She also proposed ways to lower prescription-drug costs, including requiring drug companies to redirect funds from marketing to research, encouraging the development of generics to increase competition for prescription drugs, allowing Americans to import drugs from abroad, demanding higher rebates for prescription drugs through Medicare, and allowing Medicare to negotiate drug and biologic prices.
Clinton also drew attention to her strong feelings about the health care industry earlier this month at the Democratic primary debate in Las Vegas, where moderator Anderson Cooper asked the candidates which enemy they were most proud of.
"Well, in addition to the NRA, the health-insurance companies, the drug companies, the Iranians," Clinton answered, amid laughter, "probably the Republicans."